Fc Variant Knob-Hole Engineering for Heterodimer Assembly
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing heteromultimeric proteins, such as multispecific antibodies, face challenges including low yield, production of mixed products, and reduced effector function due to inefficient production processes and chemical modifications that alter protein integrity.
Innovation Solution
Development of Fc variants with specific amino acid modifications, particularly at residues 241 and 243, to improve yield and reduce mispairing, along with methods for expressing these variants in host cells like CHO or E. coli, facilitating efficient production of heterodimers with enhanced purity and homogeneity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical cross-linking is used to produce bispecific antibodies, then binding specificity is improved, but manufacturing complexity and loss of substance increase due to labor intensive purification and protein integrity alteration
Solution Approach 1:
The patent replaces chemical cross-linking methods with a biological system using engineered Fc variants that self-assemble into heterodimers through modified interaction interfaces. This substitution eliminates the need for chemical reagents and complex purification steps, directly resolving the contradiction between achieving specific binding and maintaining ease of manufacture
Solution Approach 2:
The patent modifies amino acid parameters at specific positions (241 and 243) in the Fc region to create variants with altered dimerization properties. These parameter changes enable selective heterodimer formation without chemical modification, improving both binding specificity and manufacturing simplicity by eliminating chemical cross-linking requirements
2Adaptability or versatility
If cell-fusion technology is used to produce heteromultimeric proteins, then binding diversity is improved, but productivity decreases due to random assembly and low yield of desired products
Solution Approach 1:
The patent introduces asymmetric modifications at positions 241 and 243 in the Fc region, creating 'knob' and 'hole' variants that are incompatible with homodimer formation. This asymmetry ensures that only heterodimers can form, eliminating the random assembly problem and dramatically improving productivity while maintaining binding diversity
Solution Approach 2:
The patent performs preliminary engineering of the Fc region to create complementary surfaces before protein expression. By pre-designing the knob and hole structures, the system ensures correct heterodimer assembly occurs naturally during expression, eliminating the need for post-production purification and significantly increasing yield of functional bispecific antibodies
3Reliability
If conventional Fc regions are used in heteromultimeric proteins, then effector function is maintained, but manufacturing precision decreases due to homodimer formation and mispairing
Solution Approach 1:
The patent applies localized modifications only at positions 241 and 243 in the Fc region, leaving the rest of the Fc structure intact to maintain effector functions. This local quality change creates steric incompatibility for homodimer formation while preserving the functional regions, thereby improving manufacturing precision without sacrificing reliability
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.